Groundbreaking instrument-free assay nears completion, showing promise for faster, more accurate patient care.

无需仪器的开创性检测方法接近完成，显示出更快、更准确的患者护理前景。

NEW YORK, NY, April 10, 2025 / Biotech Newswire / --

纽约，纽约州，2025年4月10日 /生物技术新闻社/ --

Chemeleon

变色龙

, a disruptive innovator in diagnostic technology, today announced a collaboration with Mayo Clinic to complete development and clinical validation of their ultra-rapid, instrument-free assay poised to redefine point-of-care (POC) testing in emergency settings. This collaboration will focus on clinical optimization of Chemeleon’s flagship high-sensitivity cardiac troponin (hs-cTn) assay and explore the application of their platform technology to other acute care conditions beyond cardiac care.

，一家诊断技术领域的颠覆性创新者，今天宣布与梅奥诊所合作，完成其超快速、无需仪器的检测方法的开发和临床验证，该方法有望重新定义急诊环境中的即时检测（POC）。此次合作将专注于优化Chemeleon的旗舰高灵敏度心肌肌钙蛋白（hs-cTn）检测，并探索其平台技术在心脏护理之外其他急性护理条件下的应用。

Coinciding with this milestone, the company has launched a $10M Series A funding round to help bring this transformative technology to market..

与此同时，该公司已启动了一轮1000万美元的A轮融资，以帮助将这项变革性技术推向市场。

The ultra-rapid, POC assay leverages Chemeleon’s patented Binding-Induced Nanostructured Dynamic Surface (BINDS™) technology to deliver results in seconds rather than hours, dramatically accelerating clinical-decision making and transforming patient outcomes. Collaborating with Mayo Clinic enables enhanced clinical validation, diagnostic protocol optimization, and a clear path to adoption.

超快速的POC检测利用了Chemeleon公司专利的结合诱导纳米结构动态表面（BINDS™）技术，在数秒内提供结果，而非数小时，极大地加快临床决策并改善患者预后。与梅奥诊所的合作有助于加强临床验证、优化诊断方案，并为采用铺平道路。

“With Mayo Clinic’s deep clinical expertise, we’re accelerating a future where faster diagnosis can mean faster treatment for life-threatening conditions in and out of the emergency department,” .

“凭借梅奥诊所深厚的临床专业知识，我们正在加速推进一个未来：更快的诊断可以意味着在急诊室内外对危及生命的状况进行更快的治疗。”

said Brendan Walker, CEO of Chemeleon.

布伦丹·沃克（Brendan Walker），Chemeleon首席执行官表示。

The Series A will fund clinical trials, FDA clearance, and initial market entry into a $15 billion acute care diagnostics market. Investors interested in exploring this opportunity can join a briefing on Wednesday, April 16th at 2:00 PM ET (

A轮融资将用于资助临床试验、FDA审批以及进入一个150亿美元的急性护理诊断市场初期阶段。有兴趣了解此机会的投资者可以参加4月16日星期三东部时间下午2点举行的简报会。

REGISTER HERE

在此注册

) or Wednesday, April 23rd at 2:00 PM ET

）或 4 月 23 日星期三下午 2:00（东部时间）

(REGISTER HERE)

（在此注册）

to learn more.

了解更多。

About

关于

Chemeleon

变色龙

Chemeleon develops ultra-rapid, instrument-free, POC assays that deliver lab-precision results at the point of need. By enabling faster clinical decision-making, Chemeleon’s patented technology is designed to improve patient outcomes in acute and emergency care.

Chemeleon 开发了超快速、无需仪器的即时检测（POC）分析方法，可在需要的地方提供实验室精度的结果。通过加快临床决策速度，Chemeleon 的专利技术旨在改善急性病和急诊护理中的患者预后。

Mayo Clinic has a financial interest in the technology referenced in this press release. Mayo Clinic will use any revenue it receives to support its not-for-profit mission in patient care, education and research.

梅奥诊所对该新闻稿中提到的技术拥有财务利益。梅奥诊所将利用其获得的任何收入来支持其在患者护理、教育和研究方面的非营利使命。

Contact

联系

Chemeleon

变色龙

Brendan Walker

布伦丹·沃克

This email address is being protected from spambots. You need JavaScript enabled to view it.

该电子邮件地址正受到免垃圾邮件程序的保护。您需要启用 JavaScript 才能查看它。

.

。

Keywords: Investments; Capital Financing; Point-of-Care Systems; Point-of-Care Testing; Technology; Decision Making; Troponin I; Chemeleon; Mayo Clinic; ultra-rapid assay; Series A; diagnostic technology; clinical validation; POC testing; emergency settings; high-sensitivity cardiac troponin (hs-cTn) assay; acute care conditions; Binding-Induced Nanostructured Dynamic Surface (BINDSTM); clinical decision-making; patient outcomes; clinical trials; FDA clearance; acute care diagnostics market; emergency care.

关键词：投资；资本融资；即时检验系统；即时检验；技术；决策；肌钙蛋白I；Chemeleon；梅奥诊所；超快速检测；A轮融资；诊断技术；临床验证；POC检测；急诊环境；高灵敏度心肌肌钙蛋白（hs-cTn）检测；急性护理条件；结合诱导纳米结构动态表面（BINDSTM）；临床决策；患者结果；临床试验；FDA批准；急性护理诊断市场；急诊护理。

Source: Biotech Newswire

来源：生物技术新闻社